Lợi ích của việc chuyển đổi bệnh nhân nữ tâm thần phân liệt sang aripiprazole: một nghiên cứu ca lâm sàng và tổng quan ngắn về tài liệu

Aihara K, Shimada J, Miwa T et al (2004) The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Brain Res 1003:9–17 American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders text rev, 4th edn. American Psychiatric Association Press, Washington, DC Anghelescu I, Wolf J (2004) Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report. J Clin Psychiatry 65:1286–1287 Burris KD, Molski TF, Xu C et al (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. Pharmacol Exp Ther 302:381–389 Byerly MJ, Marcus RN, Tran QV et al (2009) Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res 107:218–222 Casey DE, Carson WH, Saha AR et al (2003) Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 166:391–399 Chen CH, Huang MC, Lu ML (2008) Aripiprazole resolves symptomatic hyperprolactinemia in a male schizophrenic patient. Prog Neuropsychopharmacol Biol Psychiatry 32:893–894 Haddad PM, Wieck A (2004) Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64:2291–2314 Jordan S, Koprivica V, Chen R et al (2002) The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441:137–140 Kay SR, Fiszbein A, Opler LA (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276 Kim CY, Chung S, Lee JN et al (2009) A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. Int Clin Psychopharmacol 24:181–188 Kinon BJ, Basson BR, Gilmore JA et al (2000) Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J Clin Psychiatry 61:833–840 Lee BH, Kim YK, Park SH (2006) Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 30:714–717 Lorenz RA, Weinstein B (2007) Resolution of haloperidol-induced hyperprolactinemia with aripiprazole. J Clin Psychopharmacol 27:524–525 Lu ML, Shen WW, Chen CH (2008) Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry 32:1978–1981 Mamo D, Graff A, Mizrahi R et al (2007) Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry 164:1411–1417 Marder SR, McQuade RD, Stock E et al (2003) Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 61:123–136 Mir A, Shivakumar K, Williamson RJ et al (2008) Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol 22:244–253 Montejo AL (2008) Prolactin awareness: an essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol 18:108–114 Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799–812 Pae CU, Serretti A, Chiesa A et al (2009) Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. Eur Neuropsychopharmacol 19:562–570 Paulzen M, Gründer G (2007) Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole. Int J Neuropsychopharmacol 10:149–151 Peuskens J (2000) Switching approach in the management of schizophrenia patients. Int Clin Psychopharmacol 15:15–19 Potkin SG, Saha AR, Kujawa MJ et al (2003) Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60:681–690 Raja M (2007) Improvement or worsening of psychotic symptoms after treatment with low doses of aripiprazole. Int J Neuropsychopharmacol 10:107–110 Ramaswamy S, Vijay D, William M et al (2004) Aripiprazole possibly worsens psychosis. Int Clin Psychopharmacol 19:45–48 Remington G, Chue P, Stip E et al (2005) The crossover approach to switching antipsychotics: what is the evidence? Schizophr Res 76:267–272 Shim JC, Shin JG, Kelly DL et al (2007) Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 164:1404–1410 Szarfman A, Tonning JM, Levine JG et al (2006) Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 26:748–758 Wahl R, Ostroff R (2005) Reversal of symptomatic hyperprolactinemia by aripiprazole. Am J Psychiatry 162:1542–1543 Weiden PJ, Buckley PF (2007) Reducing the burden of side effects during long-term antipsychotic therapy: the role of “switching” medications. J Clin Psychiatry 68:14–23 Wolf J, Fiedler U (2007) Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole. J Clin Pharm Ther 32:197–198